![]() | |
Enghraifft o: | math o endid cemegol ![]() |
---|---|
Math | (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(2R,3S,4R)-5-{[(1R,3S,5R,6S)-3,5-diamino-2-{[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol ![]() |
Màs | 615.296 uned Dalton ![]() |
Fformiwla gemegol | C₂₃h₄₅n₅o₁₄ ![]() |
Enw WHO | Paromomycin ![]() |
Clefydau i'w trin | Cryptosporidiosis, amebiasis ![]() |
Beichiogrwydd | Categori beichiogrwydd unol daleithiau america n ![]() |
Rhan o | paromomycin metabolic process, paromomycin catabolic process, paromomycin biosynthetic process ![]() |
Gwneuthurwr | Pfizer ![]() |
![]() |
Mae paromomycin yn wrthfiotic a ddefnyddir i drin nifer o heintiau gan gynnwys amebiasis, giardiasis, leishmaniasis, a heintiau llyngyr rhuban.[1] Y fformiwla cemegol ar gyfer y cyffur hwn yw C₂₃H₄₅N₅O₁₄.